Japan · Delayed Price · Currency is JPY Olympus Earnings Call Transcripts
Fiscal Year 2026
-
Q4 delivered strong sales in North America and robust global performance, with new products driving growth. Strategic review of the surgical segment is underway, and quality remediation costs are set to decline as Project Elevate concludes.
-
Revenue guidance was revised down due to ship holds and U.S. GI execution issues, but Q4 growth is expected as corrective actions take effect. FDA-related product holds and recalls impacted costs and margins, but long-term margin and growth targets remain unchanged.
-
The medium-term plan targets steady revenue and margin growth, driven by innovation, restructuring, and disciplined capital allocation. Guidance is conservative, with upside potential from new product launches and market recovery, especially in China and the US.
-
Q1 FY2026 saw a 12% revenue decline and a 65% drop in adjusted operating profit, driven by tough comps, delayed purchases, and regulatory/tariff headwinds. Management expects recovery from Q2 with new product launches, cost control, and local production in China.
Fiscal Year 2025
-
FY2025 saw record revenue and strong profit growth, led by North America, despite China headwinds and supply chain disruptions. FY2026 guidance anticipates steady growth, increased R&D investment, higher dividends, and a major share buyback, with U.S. tariff risks being closely monitored.
-
Revenue grew 9% year-on-year, led by strong North American and SEA performance, but China’s ongoing challenges prompted a downward revision in full-year guidance. Adjusted operating profit and margins improved, with management targeting a return to 20%+ margins in the medium term.
-
Record-high revenue and double-digit growth in core segments were achieved in fiscal 2023, with operating margin reaching 20%. Fiscal 2024 guidance projects continued growth, increased dividends, and major investments in quality and innovation, amid ongoing regulatory and market challenges.
-
Q1 FY2025 saw 15% revenue growth and 21% higher operating profit, driven by strong North America performance and cost control. China remains a challenge, but guidance is unchanged, with robust U.S. growth and ongoing quality improvements supporting the outlook.